Karachi: Liven Pharma Limited, a company listed in the pharmaceutical sector, has released its financial statement for the fiscal year ending June 30, 2026. According to the report, the company experienced notable financial shifts, demonstrating a mix of progress and ongoing challenges.

The total assets of Liven Pharma Limited increased to 1.22 billion Rupees by June 2026, up from 822.90 million Rupees in the previous year. This rise in assets was largely attributed to an increase in property, plant, and equipment, which saw a substantial escalation from 666.51 million Rupees to 918.16 million Rupees, marking a very large or significant move of 37.79%. Furthermore, the company made strategic short-term investments amounting to 163.30 million Rupees, a new development as there were no such investments recorded in the previous fiscal year.

In terms of equity, the issued, subscribed, and paid-up share capital expanded to 1.13 billion Rupees from 930.40 million Rupees, reflecting a very large or significant move of 21.50%. The company also reported a surplus on revaluation of property, plant, and equipment of 188.91 million Rupees, which was not present in the prior fiscal year, further boosting its equity position.

However, Liven Pharma continued to face operational hurdles. The company's sales declined moderately to 105.81 million Rupees from 127.27 million Rupees, while cost of sales decreased to 79.16 million Rupees from 109.31 million Rupees, resulting in a gross profit increase to 26.65 million Rupees from 17.96 million Rupees.

Despite the rise in gross profit, Liven Pharma's administrative and general expenses remained high at 37.71 million Rupees, although significantly reduced from the previous year's 373.56 million Rupees. The company also reported an operating loss of 77.14 million Rupees, an improvement from the 490.90 million Rupees loss recorded last year.

According to information available from the Pakistan Stock Exchange (PSX), the firm managed to reduce its overall loss after taxation to 31.14 million Rupees, a big move from the previous year’s loss of 584.46 million Rupees. Loss per share was likewise reduced to 0.28 Rupees from 7.11 Rupees, indicating progress in financial management and operational efficiency.

The liabilities of the company increased to 230.58 million Rupees from 189.04 million Rupees. Non-current liabilities rose to 119.31 million Rupees, primarily due to an increase in deferred taxation, which climbed to 114.45 million Rupees from 92.27 million Rupees. Current liabilities also saw an increase, totaling 111.27 million Rupees, up from 90.43 million Rupees.

Liven Pharma Limited's financial report reflects a year of strategic asset management and capital restructuring, despite facing continuous operational challenges in the pharmaceutical sector.